Evidence map›Paper›PMID 29845462›Full record

ArticleUpdates in surgery2018

Surgical treatment of hepatic metastases from gastric cancer.

Silvia Ministrini, Leonardo Solaini, Chiara Cipollari, Silvia Sofia, Elisabetta Marino, Alessia D'Ignazio, Maria Bencivenga, Guido A M Tiberio

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Updates in surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Surgical management of metastatic gastric cancer: moving beyond the guidelines.Translational gastroenterology and hepatology · 2019
    Review
  18. Advanced gastric cancer: the value of surgery.Acta bio-medica : Atenei Parmensis · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Silvia MinistriniGeneral Surgery, University of Brescia, piazzale Spedali Civili, 1, 25123, Brescia, Italy. silvia.ministrini@hotmail.it.ORCID http://orcid.org/0000-0001-9209-5040
Leonardo SolainiGeneral Surgery, Forlì Hospital, Forlì, Italy.
Chiara CipollariGeneral Surgery, University of Verona, Verona, Italy.
Silvia SofiaGeneral Surgery, University of Torino, Turin, Italy.
Elisabetta MarinoGeneral Surgery, University of Perugia, Perugia, Italy.
Alessia D'IgnazioGeneral Surgery, University of Siena, Siena, Italy.
Maria BencivengaGeneral Surgery, University of Verona, Verona, Italy.
Guido A M TiberioGeneral Surgery, University of Brescia, piazzale Spedali Civili, 1, 25123, Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of the study was to investigate the clinical factors influencing the prognosis of patients submitted to hepatectomy for metastases from gastric cancer and their clinical role. We conducted a retrospective multicentre review. We evaluated how survival from surgery was influenced by patient-related, tumour-related and treatment-related prognostic factors. We analysed data on 144 patients submitted to hepatectomy for metastases from gastric cancer, in the synchronous and metachronous setting. In 117 cases, an R0 resection was achieved, while in 27 an R + hepatic resection was performed. Chemotherapy was administered to 55 patients. Surgical mortality was 2.1% and morbidity 21.5%. One-, 3-, and 5-year OS rates after surgery were 49.9, 19.4 and 11.6%, respectively, with a median OS of 12.0 months. T4 gastric cancer, H3 hepatic involvement, non-curative resection, recurrence after surgery, and abstention from chemotherapy were associated with a worse prognosis. Factor T and H displayed a clear (p < 0.001) cumulative effect. Our data show that R0 resection must be pursued whenever possible. The treatment of T4 gastric cancer with hepatic bilateral and diffuse metastasis (H3) should be considered carefully or it should be probably avoided. Finally, a multimodal treatment associating surgery and chemotherapy offers the best survival results.

Indexed as

AdultAgedAged, 80 and overFemaleFollow-Up StudiesHepatectomyHumansLiver NeoplasmsMaleMiddle AgedPrognosisRetrospective StudiesStomach NeoplasmsSurvival AnalysisCurative surgeryGastric cancerHepatic metastasis

Identifiers

PMID29845462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.